Real-World Experience with Dolutegravir-Based Two-Drug Regimens

Viral Failure Among Persons Living with HIV Initiating Dolutegravir-Based vs. Other Recommended Regimens in Real-World Clinical Care Settings

Real-World Single-Center Experience with Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Patients

Background/Aims The approval of sofosbuvir (SOF), a direct-acting antiviral, has revolutionized the treatment of chronic hepatitis C virus (HCV). Methods We assessed the sustained virological response (SVR) of SOF-based regimens in a real-world single-center setting for the treatment of chronic HCV genotype 1 (G1) patients. This was a retrospective review of chronic HCV G1 adult patients trea...

Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice.

OBJECTIVE Dolutegravir (DGV) is one of the preferred antiretroviral agents in first-line combination antiretroviral therapy (cART). Though considered to be a well tolerated drug, we aimed to determine the actual rate, timing and detailed motivation of stopping DGV in a real-life clinical setting. DESIGN A cohort study including all patients who started DGV in two HIV treatment centers in The ...

Real-world Experience with Sofosbuvir-based Regimens for Chronic Hepatitis C, Including Patients with Factors Previously Associated with Inferior Treatment Response.

The introduction of sofosbuvir, a direct acting antiviral, has revolutionized the treatment of chronic hepatitis C virus (HCV). Phase 3 clinical trials have demonstrated the efficacy, simplicity, and tolerability of sofosbuvir-based regimens and report high rates of sustained virological response (SVR) rates. The purpose of this study was to assess whether clinical trial findings translate into...

Real-world medication persistence with single versus multiple tablet regimens for HIV-1 treatment

INTRODUCTION Adherence to antiretroviral (ARV) treatment for HIV-1 is crucial to achieving optimal clinical outcomes. Simplification of regimens with once-daily single-tablet regimens (STRs) can improve adherence compared to multi-tablet regimens (MTRs). This study compared real-world persistence (a proxy for treatment effectiveness and adherence) between HIV-1 infected patients receiving STRs ...